Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI118647

Cellular bioenergetics after erythropoietin therapy in chronic renal failure.

R M Marrades, J Alonso, J Roca, J M González de Suso, J M Campistol, J A Barberá, O Diaz, J V Torregrosa, J R Masclans, R Rodríguez-Roisin, and P D Wagner

Servei de Pneumologia i Al.lèrgia respiratòria, Hospital Clínic, Universitat de Barcelona, Spain.

Find articles by Marrades, R. in: PubMed | Google Scholar

Servei de Pneumologia i Al.lèrgia respiratòria, Hospital Clínic, Universitat de Barcelona, Spain.

Find articles by Alonso, J. in: PubMed | Google Scholar

Servei de Pneumologia i Al.lèrgia respiratòria, Hospital Clínic, Universitat de Barcelona, Spain.

Find articles by Roca, J. in: PubMed | Google Scholar

Servei de Pneumologia i Al.lèrgia respiratòria, Hospital Clínic, Universitat de Barcelona, Spain.

Find articles by González de Suso, J. in: PubMed | Google Scholar

Servei de Pneumologia i Al.lèrgia respiratòria, Hospital Clínic, Universitat de Barcelona, Spain.

Find articles by Campistol, J. in: PubMed | Google Scholar

Servei de Pneumologia i Al.lèrgia respiratòria, Hospital Clínic, Universitat de Barcelona, Spain.

Find articles by Barberá, J. in: PubMed | Google Scholar

Servei de Pneumologia i Al.lèrgia respiratòria, Hospital Clínic, Universitat de Barcelona, Spain.

Find articles by Diaz, O. in: PubMed | Google Scholar

Servei de Pneumologia i Al.lèrgia respiratòria, Hospital Clínic, Universitat de Barcelona, Spain.

Find articles by Torregrosa, J. in: PubMed | Google Scholar

Servei de Pneumologia i Al.lèrgia respiratòria, Hospital Clínic, Universitat de Barcelona, Spain.

Find articles by Masclans, J. in: PubMed | Google Scholar

Servei de Pneumologia i Al.lèrgia respiratòria, Hospital Clínic, Universitat de Barcelona, Spain.

Find articles by Rodríguez-Roisin, R. in: PubMed | Google Scholar

Servei de Pneumologia i Al.lèrgia respiratòria, Hospital Clínic, Universitat de Barcelona, Spain.

Find articles by Wagner, P. in: PubMed | Google Scholar

Published May 1, 1996 - More info

Published in Volume 97, Issue 9 on May 1, 1996
J Clin Invest. 1996;97(9):2101–2110. https://doi.org/10.1172/JCI118647.
© 1996 The American Society for Clinical Investigation
Published May 1, 1996 - Version history
View PDF
Abstract

After erythropoietin (rHuEPO) therapy, patients with chronic renal failure (CRF) do not improve peak O2 uptake (VO2 peak) as much as expected from the rise in hemoglobin concentration ([Hb]). In a companion study, we explain this phenomenon by the concurrent effects of fall in muscle blood flow after rHuEPO and abnormal capillary O2 conductance observed in CRF patients. The latter is likely associated with a poor muscle microcirculatory network and capillary-myofiber dissociation due to uremic myopathy. Herein, cellular bioenergetics and its relationships with muscle O2 transport, before and after rHuEPO therapy, were examined in eight CRF patients (27 +/- 7.3 [SD] yr) studied pre- and post-rHuEPO ([Hb] = 7.8 +/- 0.7 vs. 11.7 +/- 0.7 g x dl-1) during an incremental cycling exercise protocol. Eight healthy sedentary subjects (26 +/- 3.1 yr) served as controls. We hypothesize that uremic myopathy provokes a cytosolic dysfunction but mitochondrial oxidative capacity is not abnormal. 31P-nuclear magnetic resonance spectra (31P-MRS) from the vastus medialis were obtained throughout the exercise protocol consisting of periods of 2 min exercise (at 1.67 Hz) at increasing work-loads interspersed by resting periods of 2.5 min. On a different day, after an identical exercise protocol, arterial and femoral venous blood gas data were obtained together with simultaneous measurements of femoral venous blood flow (Qleg) to calculate O2 delivery (QO2leg) and O2 uptake (VO2leg). Baseline resting [phosphocreatine] to [inorganic phosphate] ratio ([PCr]/[Pi]) did not change after rHuEPO (8.9 +/- 1.2 vs. 8.8 +/- 1.2, respectively), but it was significantly lower than in controls (10.9 +/- 1.5) (P = 0.01 each). At a given submaximal or peak VO2leg, no effects of rHuEPO were seen on cellular bioenergetics ([PCr]/[Pi] ratio, %[PCr] consumption halftime of [PCr] recovery after exercise), nor in intracellular pH (pHi). The post-rHuEPO bioenergetic status and pHi, at a given VO2leg, were below those observed in the control group. However, at a given pHi, no differences in 31P-MRS data were detected between post-rHuEPO and controls. After rHuEPO, at peak VO2, Qleg fell 20% (P < 0.04), limiting the change in QO2leg to 17%, a value that did not reach statistical significance. The corresponding O2 extraction ratio decreased from 73 +/- 4% to 68 +/- 8.2% (P < 0.03). These changes indicate that maximal O2 flow from microcirculation to mitochondria did not increase despite the 50% increase in [Hb] and explain how peak VO2leg and cellular bioenergetics (31P-MRS) did not change after rHuEPO. Differences in pHi, possibly due to lactate differences, between post-rHeEPO and controls appear to be a key factor in the abnormal muscle cell bioenergetics during exercise observed in CRF patients.

Version history
  • Version 1 (May 1, 1996): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts